Linda Yaccarino’s subsequent position after departing X as CEO might be one other chief govt position at eMed Population Health, an AI startup constructing a tech platform for sufferers utilizing GLP-1s.
Yaccarino was a longtime promoting govt at NBCUniversal, however left to affix X as CEO for 2 years, the place she managed to have a optimistic affect on the social community’s troubled advert income mannequin, regardless of her and Elon Musk’s shared method to minimizing content material moderation.
Although Yaccarino doesn’t have expertise in well being tech, eMed mentioned in a press launch that they sought her out for her “plain means to barter new partnerships” — it actually additionally helps that her tenure at X made her well-known within the tech world, drawing extra eyes towards the startup.
eMed previously produced a tech platform that was designed for use with at-home COVID-19 fast antigen checks, guiding customers by the method of administering these checks correctly. Now, eMed is concentrated on GLP-1s, the category of medicine like Ozempic, which can be utilized for each weight administration and remedy of sort II diabetes.
“To be a frontrunner in right now’s healthcare market, firms have to have a fearless tenacity that permits them to not solely develop, however to even be courageous sufficient to step ahead and redefine a complete business,” Yaccarino said in a press launch. “We’re very well-positioned to be that tenacious chief, striving towards our final purpose of bettering world healthcare outcomes by our groundbreaking providers and platforms.”